Tesofensine for weight loss: what the trials actually found

What did @myfitmed actually say?

Jay Patel from MyFitMed described tesofensine as a "skinny happy pill" that doubles as a mood booster, calling it "the perfect oral peptide for improving your mood, losing belly fat and improving your overall metabolism." He said it was originally developed for Alzheimer's and Parkinson's disease, works as a serotonin, noradrenaline, and dopamine reuptake inhibitor, and that studies show significant improvements in appetite, satiety, body composition, depression symptoms, insulin sensitivity, and neuroprotection. He also called it an "oral peptide," which is a specific and consequential classification worth examining closely.

The core pitch here is straightforward: tesofensine is a neurologically active weight loss compound with antidepressant-adjacent effects. That framing is not entirely wrong, but it glosses over a lot of inconvenient details, including the compound's regulatory status, its side effect profile, and the actual state of the clinical evidence.

Does the science back this up?

Partially. The weight loss data is actually pretty compelling, but the mental health claims are significantly overstated, and the "oral peptide" label is just scientifically incorrect.

The most-cited tesofensine trial is Astrup et al. (2008, The Lancet), a randomized controlled trial of 203 obese patients over 24 weeks. Participants on 0.5 mg/day lost an average of 12.8 kg, compared to 2.2 kg on placebo. That is genuinely impressive for an oral compound. A follow-up analysis by Sjödin et al. (2010, International Journal of Obesity) confirmed reductions in visceral fat specifically, so the belly fat claim has some grounding.

On mood and depression: the clinical picture is murkier. The triple reuptake mechanism does resemble antidepressants pharmacologically. But calling tesofensine a proven mood-improver or claiming it "improves the symptoms of depression" as a demonstrated benefit overstates what the evidence actually shows. No large, controlled depression-outcome trials have been published. The Alzheimer's development history is accurate (NeuroSearch originally developed it for neurodegeneration), but the neuroprotection claim in otherwise healthy people is speculative at best.

What did they get wrong (or right)?

The biggest factual error is calling tesofensine an "oral peptide." It is not a peptide. Peptides are chains of amino acids. Tesofensine is a small-molecule monoamine reuptake inhibitor, structurally similar to compounds like sibutramine, which was pulled from the US market in 2010 due to cardiovascular risks (James et al., 2010, New England Journal of Medicine). Calling it a peptide is either a misunderstanding of pharmacology or a marketing framing designed to make it sound safer and more natural than it is.

What he got right: the mechanism (triple reuptake inhibition) is accurately described. The original neurological development context is correct. The weight loss magnitude from the Astrup trial is real. The visceral fat reduction finding is supported by data.

What he got wrong or omitted: tesofensine is not FDA-approved for any indication. It is not approved in the US. The side effects, including elevated heart rate, dry mouth, insomnia, and nausea, are absent from this video entirely. The cardiovascular signal that tanked sibutramine is directly relevant here and was not mentioned. The mood and depression benefits are presented as established when they are not.

What should you actually know?

Tesofensine is a real compound with real weight loss data behind it, but the regulatory and safety picture is not what this video implies. It is not FDA-approved. It is available through some compounding pharmacies in the US, but that comes with the standard caveats: compounded medications are not evaluated by the FDA for safety or efficacy, and quality can vary significantly between compounders.

The cardiovascular concern is the one that deserves more airtime than it got here, which is zero. Sibutramine, a similarly acting dual reuptake inhibitor, was removed from the US market after the SCOUT trial showed increased rates of nonfatal heart attack and stroke in high-risk patients (James et al., 2010, NEJM). Tesofensine has a similar mechanism and has shown increases in heart rate in clinical trials. Anyone with hypertension, arrhythmia, or existing cardiovascular risk should ask very specific questions before considering this compound.

The "skinny happy pill" framing is doing a lot of work here. Weight loss medications are medical interventions with real risk profiles. Presenting tesofensine as a mood-enhancing metabolism optimizer without mentioning its unapproved status, its cardiovascular signal, or the limits of the mental health evidence is not balanced health information.